Ustekinumab biosimilar(DM Bio)

乌司奴单抗生物类似药（DM Bio）

Report date: 2026/05/18 20:02:07

Base Information

Drug NameUstekinumab biosimilar(DM Bio)
Drug Alias Nameustekinumab-srlfIMULDOSAAbsimkyDA-3115DMB-3115
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12Interleukin-23
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[4] 
Global Approved IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/10/11
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDong-A Pharmaceutical Co LtdMeiji Seika Pharmatech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMeiji Seika Pharmatech Co LtdAccord Healthcare SluDong-A ST Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease
Inactive IndicationsColitis, Ulcerative

Other Information

ATC CodeL04AC05
Related LinksN/A